In a recent randomized.

In a recent randomized, double-blind, Placebo – controlled Phase II field trial the TD vaccine demonstrated excellent immunogenicity and reduced the risk of clinically significant diarrhea in U.S. Travelers to Mexico and Guatemala. The Phase III study was to confirm the efficacy of the investigational drug vaccine patch for the prevention of moderate to severe diarrhea in a similar field setting.

Of encouraging Phase II data in the Pseudomonas vaccine program and the imminent clinical entry of the company reported novel investigational C. Difficile vaccine R & D resources will be even stronger. On the development of nosocomial franchise Hospital-acquired infections are a major health need and Intercell is positioned to help its portfolio, these medical need.. Following the success of the S. Aureus vaccine candidate with recent positive Phase II data by Intercell’s partner Merck & Co. Continue reading “In a recent randomized.”